Lyell's syndrome skin lesions treated by Veloderm® [25]

Journal of the European Academy of Dermatology and Venereology

Volumn 21, Issue 3, 2007, Pages 426-427

  Melandri, Davmelan ^a  

^a Bufalini Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BIOMATERIAL; CELLULOSE; CHLORHEXIDINE; EMOLLIENT AGENT; IMMUNOGLOBULIN; LAMOTRIGINE;

ADULT; CASE REPORT; COST CONTROL; ERYTHEMA; GAUZE DRESSING; HEPATITIS; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITAL DISCHARGE; HUMAN; INTENSIVE CARE UNIT; LETTER; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; ORAL MUCOSAL DISEASE; PRIORITY JOURNAL; RASH; REHYDRATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; WOUND HEALING;

ADULT; EPIDERMAL NECROLYSIS, TOXIC; HUMANS; MALE; OCCLUSIVE DRESSINGS; POLYSACCHARIDES; TRIAZINES; WOUND HEALING;

EID: 33846945026     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01919.x     Document Type: Letter

References (9)

1. Lyell A. Toxic epidermal necrolysis: An eruption resembling scalding of the skin. Br J Dermatol 1956; 68: 355-361.
2. US Department of Health and Human Services, Food and Drug Administration. Guidance for Industry. Chronic Cutaneous Ulcer and Burn Wounds - Developing Products for Treatment. Draft guidance, June 2000.
3. Birchall N, Langdon R, Cuono C, McGuire J. Toxic epidermal necrolysis: an approach to management using cryopreserved allograft skin. J Am Acad Dermatol 1987; 16: 368-372.
4. Cardoni G, Bruni S, Pellegrini C, et al. Safety and efficacy evaluation of a new biomaterial for the treatment of cutaneous losses. (In Italian.) Vascular Diseases and Therapy 2000; 1: 14-17.
5. Tucci MG, Cataldi I, Cardoni G, Mattutini G, Sigona S, Ricotti G. Safety and efficacy evaluation of a new biomaterial for the treatment of cutaneous losses. (In Italian.) Chronica Dermatologica 1996; 4.
6. Melandri D, De Angelis A, Orioli R, et al. Use of a new hemicellulose dressing (Veloderm®) for the treatment of split-thickness skin graft donor sites. A within-patient controlled study. Burns 2006; 32: 964-972.
7. McGee T, Munster A. Toxic epidermal necrolysis syndrome: Mortality rate reduced with early referral to regional burn center. Plast Reconstr Surg 1998; 102: 1018-1022.
8. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-493.
9. Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204: 503-512.